Alterity Therapeutics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRNAF research report →
Companyalteritytherapeutics.com
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease.
- CEO
- David A. Stamler
- IPO
- 2012
- Employees
- 10
- HQ
- Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $11.96M
- P/E
- -6.28
- P/S
- 25.54
- P/B
- 1.69
- EV/EBITDA
- -2.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.82%
- Op Margin
- -525.58%
- Net Margin
- -380.65%
- ROE
- -30.19%
- ROIC
- -31.32%
Growth & Income
- Revenue
- $5.44M · 35.32%
- Net Income
- $-12,147,828 · 36.48%
- EPS
- $-0.00 · 63.46%
- Op Income
- $-14,574,286
- FCF YoY
- 9.20%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 7.90
- Avg Volume
- 9.12K
Get TickerSpark's AI analysis on PRNAF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PRNAF Coverage
We haven't published any research on PRNAF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRNAF Report →